Clinical Trials
718 trialsComparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
Radiation Therapy Oncology Group
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie
SACHI
Hutchmed
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Seagen Inc.
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
National Cancer Institute (NCI)
Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.
Shanghai Pulmonary Hospital, Shanghai, China
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
ImmunityBio, Inc.
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
Dizal Pharmaceuticals
INTerpath-002
Merck Sharp & Dohme LLC
KANDLELIT-004
Merck Sharp & Dohme LLC
KANDLELIT-007
Merck Sharp & Dohme LLC
INTerpath-014
Merck Sharp & Dohme LLC
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen
TroFuse-007
Merck Sharp & Dohme LLC
MK-2870-009
Merck Sharp & Dohme LLC
TroFuse-019
Merck Sharp & Dohme LLC
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Merck Sharp & Dohme LLC
TROPION-Lung12
AstraZeneca
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Hoffmann-La Roche
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC
Guangdong Association of Clinical Trials
RELATIVITY1093
Bristol-Myers Squibb
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Pfizer
DUBLIN-3
BeyondSpring Pharmaceuticals Inc.
SUNRAY-01
Eli Lilly and Company
SUNRAY-02
Eli Lilly and Company
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Nuvation Bio Inc.
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Regeneron Pharmaceuticals
PACIFIC-8
AstraZeneca
PACIFIC-9
AstraZeneca
TROPION-Lung10
AstraZeneca
ARIAN
Fundación GECP
MK-7339-012
Merck Sharp & Dohme LLC
INTerpath-009
Merck Sharp & Dohme LLC
KRASCENDO 3
Hoffmann-La Roche
ADOPT-lung
ETOP IBCSG Partners Foundation
TROPION-Lung15
AstraZeneca
ERIS
Region Skane
ALKAZAR
Nuvalent Inc.
ARTEMIDELung04
AstraZeneca
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Bristol-Myers Squibb
ANVIL
National Cancer Institute (NCI)
PACIFIC-5
AstraZeneca
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
National Cancer Institute (NCI)
TROPION-Lung08
Daiichi Sankyo
neoR-TORCH
Shanghai Chest Hospital
CLEAR
National Cancer Institute (NCI)
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mirati Therapeutics Inc.
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Bristol-Myers Squibb